Approaches such as miRNA-based therapies (e.g., miR-18a-5p inhibitors), epigenetic modifiers, or THBD gene replacement techniques may represent promising avenues to counteract tumor progression and improve clinical outcomes in UCEC patients. This evidence concerns the gene THBD and neoplasm.